Study reveals common off-label dosing of direct oral anticoagulants

No­vo Nordisk is rais­ing its sales and op­er­at­ing prof­it es­ti­mates for the year thanks to its di­a­betes and an­ti-obe­si­ty semaglu­tide prod­ucts We­govy and Ozem­pic, the

First-line chemotherapy plus an investigational arginine-depleting agent improved survival in nonepithelioid pleural mesothelioma compared with chemotherapy alone, a randomized trial showed. For the study’s primary